Breast cancer 1

Breast Cancer

  • EndoPredict: Only available at Clinical Labs

    EndoPredict Clinician Page arrow icon   EndoPredict Request Form arrow icon   EndoPredict Brochure arrow icon

    Superior prognostic performance with results you can trust

    EndoPredict is the only prognostic test that provides insights into the risk of breast cancer recurrence, the benefits of chemotherapy and the suitability for extended endocrine therapy in women with ER+, HER2- primary breast cancer. EndoPredict is trusted in global clinical routine and is recommended in all major guidelines, and is performed locally in Australia by Clinical Labs with partial Medicare rebate available to eligible patients.

    Target group check

    Scroll indicator
    HER2 negativeLymph node positive or negativeTumour size pT1 to pT3
    ER positivePre- and postmenopausalGrade 1 to 3
    Scroll indicator

    Visit our dedicated EndoPredict Clinician page for more detailed information.

  • Somatic Mutation: Solid Tissue Molecular Profiling in Breast Cancer

    Somatic Mutation Brochure arrow icon   Somatic Mutation Request Form arrow icon

    In breast cancer, oncogenic mutations in PIK3CA or ERBB2 amplification (along with TP53 mutations) occur in ~25% of cases1,2. As such, mutated PI3K has become an attractive therapeutic target in breast cancer therapy, and a number of agents targeting the PI3K pathway are currently in clinical development3.

    Genes sequenced in this panel include:

    Scroll indicator
    PIK3CATP53
    AKT1PTEN
    ERBB2
    Scroll indicator

    How to Order Somatic Mutation Breast Cancer Gene Panel

    When to Order:

    • At diagnosis.

    Request Form Instructions:

    • Fill out our Somatic Mutation testing request form and tick the Somatic Mutation test panel required.

    Specimen Details:

    • Fresh formalin-fixed paraffin-embedded (FFPE) of 5-10 μm thickness from the tumour tissue.

    Test Cost:

    • No Medicare rebate available. An out-of-pocket fee of $400 applies.

    Turnaround Time:

    • 5-7 business days from the sample receipt date.

    Notes:

    • A negative result does not rule out the presence of a mutation that may be present but below the limits of detection for this assay (<1%).

    References:
    1. Lee JW, et al., (2005) Oncogene 24(8):1477–1480.
    2. Levine DA, (2005)     Clin Cancer Res 11(8):2875–2878.
    3. Malone E et al., Genome Medicine (2020). Molecular profiling for precision cancer therapies 12:8.

About the Author

Associate Professor Mirette Saad

Associate Professor Mirette Saad

MBBS(Hons) MD(Hons) MAACB FRCPA PhD

Associate Professor Mirette Saad

MBBS(Hons) MD(Hons) MAACB FRCPA PhD
Location: Clayton (VIC)
Speciality: Chemical Pathology
Areas of Interest:
  • antenatal screening
  • cancer genetics
  • clinical research and medical teaching
  • endocrine
  • fertility testing
  • molecular genetics
  • nipt
  • precision medicine
About

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from overseas. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for NIPT, antenatal screening, personalised drug therapy and cancer.